Introduction
Fabry disease is an X-linked inherited lysosomal storage disorder with progressive multisystemic manifestations. 1 Gastrointestinal (GI) symptoms are among the most common and most significant clinical manifestations and may include abdominal pain (often associated with meals and stress), bloating, early satiety, intermittent / chronic diarrhea, constipation, recurrent nausea and vomiting, and poor weight gain/weight loss. 2, 3 Onset of GI symptoms often occurs at young age and tend to persist into adulthood and, if patients remain untreated, reduce quality of life at all ages.
2,3

Results
Abdominal pain
Overall, 75/166 (45%) females reported abdominal pain at baseline vs. 52/166 (31%) after ≥3 years of treatment (Fig. 1) . Group comparison identified significant improvement in abdominal pain (p<0.01, Table 1 
Conclusions
These results suggest that treatment with agalsidase beta (1mg/kg/2 weeks) for ≥3 years improves both abdominal pain and diarrhea in a significant proportion of females with Fabry disease.
GI symptoms should be assessed thoroughly and managed adequately to reduce the impact on quality of life.
Further studies are needed to better understand the pathology underlying GI symptoms in Fabry disease and the mechanisms of action of ERT in the treatment of GI symptoms.
For additional information, please contact:
Patients and Methods
Females of all ages who received agalsidase beta as their first source of ERT and reported status of abdominal pain and diarrhea at baseline and also after at least 3 years of treatment were included in this analysis (n=166).
Average ERT dose: 1mg/kg/2 weeks (range 0.9 -1.1 mg/kg/2 weeks).
Baseline: Time of first agalsidase beta infusion. 
Objectives
In this study, we analyzed the effects of ≥3 years of treatment with agalsidase beta (Fabrazyme ® , Sanofi Genzyme) on GI symptoms (abdominal pain, diarrhea) in female patients with Fabry disease enrolled in the Fabry Registry.
Fabry Registry
The global Fabry Registry was initiated in 2001 as part of an effort to help healthcare professionals involved in the treatment or diagnosis of Fabry disease better understand the disease and its management and to help create Fabry disease treatment monitoring guidelines.
It is a multi-center, international, longitudinal, observational program designed to track the natural history and outcomes of patients with Fabry disease.
The Fabry Registry (NCT00196742) is sponsored by Sanofi Genzyme. (Fig. 2) . Group comparison identified significant improvement in diarrhea (p<0.01, Table 2 ).
Of 63 females reporting diarrhea at baseline, 57% reported having no diarrhea at last follow-up.
Of 97 patients reporting its absence at baseline, 16% reported diarrhea at last follow-up.
Of the 27 females who continued to have diarrhea, 93% reported improvement of their diarrhea (less intense frequency) as compared to the baseline assessment.
Parameter
Statistic Abdominal pain Diarrhea
Females with data at baseline and at Year ≥3 n 166 160
Age at first infusion Mean 
